Federal Register / Vol. 62, No. 209 / Wednesday, October 29, 1997 / Notices 56195

susceptible to a primary infection)

women of reproductive age in a

population and the rate of ALL in the

population.

Since women at risk for JV virus

infection that might result in ALL in

their child during pregnancy are those

who have not yet had a primary

infection, methods to achieve

immunization are disclosed in the

application. Since immunization could

be specifically targeted to women who

have never been exposed to JC virus, the

application also discloses methods of

screening women for prior exposure to

the virus. In addition, methods for

diagnosis of susceptibility are disclosed

which can be applied to cord blood

samples which may allow identification

of children at high risk and allow early

intervention. These methods of

screening can be performed using either

serological or molecular methods of

analysis and both types are claimed in

the application.

raf Protein Kinase Therapeutics

U Rapp, H App, SM Storm (NCI)

Serial No. 08/207,954 filed 18 Mar 94

(priority to 23 Aug 91)

Licensing Contact: Ken Hemby, 301/

496–7735 ext. 265.

Novel raf protein kinases may be

valuable for the treatment of cancers. raf

protein kinases are enzyme that

stimulate cell growth in a variety of cell

systems and, when expressed in

specifically altered forms, can initiate

malignant cell growth. These novel raf

protein kinases, which are mutant

constructs or are transcribed from raf

antisense DNA, can be used to inhibit

the activity of cellular raf protein

kinases and prevent or reverse

malignant cell growth. Other potential

areas of application include

proliferation diseases such as psoriasis

and restenosis, and inflammatory

diseases.

This research has been described in

Trends in Biochem. Sci. 19: 474–480,

1994.

Main advantages of invention: raf is

by now a verified cancer target; raf

directed drugs promise to be widely

applicable and nontoxic based on

clinical studies with antisense ODN.

Stage of development: Ready to be

used for drug screens, application in

gene therapy. Further development

required: Use of inhibitory raf mutants

in gene therapy requires clinical studies.

Dated: October 21, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 97–28623 Filed 10–28–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and

Infectious Diseases; Notice of Meeting:

Board of Scientific Counselors

Pursuant to Public Law 92–463,

notice is hereby given of the meeting of

the Board of Scientific Counselors,

National Institute of Allergy and

Infectious Diseases, at 8 a.m. on

December 8–10, 1997, National

Institutes of Health, Building 10, Rooms

433 and 413, 9000 Rockville Pike,

Bethesda, Maryland.

In accordance with the provisions set

forth in Section 552b(c)(6), Title 5,

U.S.C. and Section 10(d) of Public Law

92–463, the entire meeting will be

closed to the public for the review,

discussion, and evaluation of individual

programs and projects by the National

Institutes of Health, including

consideration of personal qualifications

and performing, the competence of

individual investigators, and similar

items, the disclosure of which would

constitute a clearly unwarranted

invasion of personal privacy.

Dr. Thomas J. Kindt, Executive

Secretary, Board of Scientific

Counselors, NIAID, NIH, Building 10,

Room 4A31, telephone 301–496–3006,

will provide substantive program

information.

(Catalog of Federal Domestic Assistance

Program No. 93–301, National Institutes of

Health)

Dated: October 21, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–28626 Filed 10–28–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of

Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following Center

for Scientific Review Special Emphasis

Panel (SEP) meetings:

Purpose/Agenda: To review individual

grant applications.

Name of SEP: Behavioral and

Neurosciences.

Date: November 14, 1997.

Time: 9:00 a.m.

Place: Capitol Holiday Inn, Washington,

DC.

Contact Person: Dr. Sam Rawlings,

Scientific Review Administrator, 6701

Rockledge Drive, Room 5160, Bethesda,

Maryland 20892, (301) 435–1243.

Name of SEP: Microbiological and

Immunological Sciences.

Date: November 18, 1997.

Time: 12:00 p.m.

Place: Holiday Inn-National Airport,

Crystal City, VA.

Contact Person: Dr. Gerald Liddel,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4186, Bethesda,

Maryland 20892, (301) 435–1150.

Purpose/Agenda: To review Small

Business Innovation Research.

Name of SEP: Behavioral and

Neurosciences.

Date: November 7, 1997.

Time: 9:00 a.m.

Place: Capitol Holiday Inn, Washington,

DC.

Contact Person: Dr. Sam Rawlings,

Scientific Review Administrator, 6701

Rockledge Drive, Room 5160, Bethesda,

Maryland 20892 (301) 435–1243.

This notice is being published less

than 15 days prior to the above meeting

due to the urgent need to meet timing

limitations imposed by the grant review

and funding cycle.

Name of SEP: Biological and Physiological

Sciences.

Date: November 20, 1997.

Time: 8:30 a.m.

Place: Doubletree Hotel, Rockville, MD.

Contact Person: Dr. Michael Micklin,

Scientific Review Administrator, 6701

Rockledge Drive, Room 5198, Bethesda,

Maryland 20892, (301) 435–1258.

Name of SEP: Biological and Physiological

Sciences.

Date: November 24, 1997.

Time: 8:00 a.m.

Place: Ramada Inn, Rockville, MD.

Contact Person: Dr. Abubakar Shaikh,

Scientific Review Administrator, 6701

Rockledge Drive, Room 6166, Bethesda,

Maryland 20892, (301) 435–1042.

The meetings will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program Nos. 93.306, 93.333, 93.337, 93.393–

93.396, 93–837–93.844, 93.846–93.878,

93.892, 93–893, National Institutes of Health,

HHS)

Dated: October 22, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–28625 Filed 10–28–97; 8:45 am]

BILLING CODE 4140–01–M